The decreased mean platelet volume is associated with poor prognosis in patients with oropharyngeal cancer treated with radiotherapy.
Biomarker
Mean platelet volume
Oropharyngeal cancer
Outcome
Prognostic factor
Journal
Radiation oncology (London, England)
ISSN: 1748-717X
Titre abrégé: Radiat Oncol
Pays: England
ID NLM: 101265111
Informations de publication
Date de publication:
07 Nov 2020
07 Nov 2020
Historique:
received:
22
08
2020
accepted:
29
10
2020
entrez:
8
11
2020
pubmed:
9
11
2020
medline:
4
8
2021
Statut:
epublish
Résumé
There is considerable evidence that platelets contribute to cancer growth and metastatic dissemination. In recent studies, altered mean platelet volume (MPV) has been associated with prognosis in different types of cancer. However, the prognostic role of the MPV in head and neck squamous cell cancer (HNSCC) is currently discussed controversially. The present study was performed to analyze and further elucidate the prognostic significance of the MPV in HNSCC. A total of 319 oropharyngeal squamous cell cancer (OPSCC) patients treated with radiotherapy at a tertiary academic center were enrolled in the present study. Kaplan-Meier method as well as uni- and multivariate Cox proportional hazards were used to evaluate the impact of MPV on cancer-specific survival (CSS), locoregional control (LC) and recurrence-free survival (RFS). The median MPV was 10.30 fL (mean 10.26 ± 1.17fL). Univariate analyses showed a significant association of the MPV with CSS (HR 0.85, 95% CI 0.74-0.98, p = 0.025), LC (HR 0.86, 95% CI 0.74-0.99, p = 0.034) and RFS (HR 0.87, 95% CI 0.76-0.996; p = 0.043). In multivariate analysis, the MPV remained an independent prognostic factor for CSS (HR 0.77, 95% CI 0.63-0.93, p = 0.008), LC (HR 0.80, 95% CI 0.65-0.98, p = 0.030), and RFS (HR 0.83, 95% CI 0.685-0.999, p = 0.049). Our findings indicate that the MPV is a prognostic marker in OPSCC patients and may contribute to future individual risk assessment.
Sections du résumé
BACKGROUND
BACKGROUND
There is considerable evidence that platelets contribute to cancer growth and metastatic dissemination. In recent studies, altered mean platelet volume (MPV) has been associated with prognosis in different types of cancer. However, the prognostic role of the MPV in head and neck squamous cell cancer (HNSCC) is currently discussed controversially. The present study was performed to analyze and further elucidate the prognostic significance of the MPV in HNSCC.
METHODS
METHODS
A total of 319 oropharyngeal squamous cell cancer (OPSCC) patients treated with radiotherapy at a tertiary academic center were enrolled in the present study. Kaplan-Meier method as well as uni- and multivariate Cox proportional hazards were used to evaluate the impact of MPV on cancer-specific survival (CSS), locoregional control (LC) and recurrence-free survival (RFS).
RESULTS
RESULTS
The median MPV was 10.30 fL (mean 10.26 ± 1.17fL). Univariate analyses showed a significant association of the MPV with CSS (HR 0.85, 95% CI 0.74-0.98, p = 0.025), LC (HR 0.86, 95% CI 0.74-0.99, p = 0.034) and RFS (HR 0.87, 95% CI 0.76-0.996; p = 0.043). In multivariate analysis, the MPV remained an independent prognostic factor for CSS (HR 0.77, 95% CI 0.63-0.93, p = 0.008), LC (HR 0.80, 95% CI 0.65-0.98, p = 0.030), and RFS (HR 0.83, 95% CI 0.685-0.999, p = 0.049).
CONCLUSIONS
CONCLUSIONS
Our findings indicate that the MPV is a prognostic marker in OPSCC patients and may contribute to future individual risk assessment.
Identifiants
pubmed: 33160368
doi: 10.1186/s13014-020-01702-4
pii: 10.1186/s13014-020-01702-4
pmc: PMC7648964
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
259Références
Thromb Res. 2016 Mar;139:65-76
pubmed: 26916298
Pharmacol Ther. 2016 Jan;157:112-9
pubmed: 26615781
Am J Clin Oncol. 2003 Apr;26(2):135-40
pubmed: 12714883
Mol Carcinog. 2019 Mar;58(3):411-425
pubmed: 30488488
Mol Clin Oncol. 2015 Jan;3(1):197-201
pubmed: 25469294
Transl Cancer Res. 2016 Aug;5(4):371-382
pubmed: 30627523
Mol Clin Oncol. 2019 Apr;10(4):457-462
pubmed: 30931118
Transl Lung Cancer Res. 2019 May;8(Suppl 1):S50-S58
pubmed: 31211105
Liver Cancer. 2019 May;8(3):203-217
pubmed: 31192156
N Engl J Med. 1993 Jan 21;328(3):159-63
pubmed: 8417381
Oral Oncol. 2009 Apr-May;45(4-5):309-16
pubmed: 18804401
Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):14205-10
pubmed: 14612570
Thromb Res. 2016 Apr;140 Suppl 1:S199-200
pubmed: 27161749
Int J Clin Oncol. 2017 Dec;22(6):1076-1080
pubmed: 28664301
Platelets. 2015;26(2):114-8
pubmed: 25192361
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
PLoS One. 2011;6(10):e26125
pubmed: 22022533
Curr Cancer Drug Targets. 2012 Feb;12(2):107-23
pubmed: 22165970
Int J Cancer. 2009 Apr 15;124(8):1773-7
pubmed: 19101987
Eur J Cancer Clin Oncol. 1984 Jul;20(7):899-903
pubmed: 6235114
Curr Pharm Des. 2011;17(1):47-58
pubmed: 21247392
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Sci Rep. 2017 Aug 31;7(1):10117
pubmed: 28860628
Cancer Epidemiol Biomarkers Prev. 2009 Dec;18(12):3368-74
pubmed: 19959684
Pancreas. 2004 Aug;29(2):132-40
pubmed: 15257105
J Clin Med. 2019 Nov 02;8(11):
pubmed: 31684119
Oncol Lett. 2016 Oct;12(4):2501-2506
pubmed: 27703523
J Obstet Gynaecol. 2013 Apr;33(3):301-4
pubmed: 23550865
Oncotarget. 2017 Jul 12;8(40):68115-68122
pubmed: 28978101
J Urol. 2017 Dec;198(6):1247-1252
pubmed: 28716649
Clin Breast Cancer. 2002 Jan;2(4):311-5
pubmed: 11899364
J Natl Compr Canc Netw. 2020 Jul;18(7):873-898
pubmed: 32634781
J Korean Assoc Oral Maxillofac Surg. 2017 Oct;43(5):305-311
pubmed: 29142864